Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,728 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
Matsubara N, Yamada Y, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S, Otsuka M, Fukasawa S. Matsubara N, et al. Among authors: yamada y. Clin Genitourin Cancer. 2017 Dec;15(6):e1073-e1080. doi: 10.1016/j.clgc.2017.07.016. Epub 2017 Jul 26. Clin Genitourin Cancer. 2017. PMID: 28826931
Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
Matsubara N, Yamada Y, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S, Otsuka M, Fukasawa S. Matsubara N, et al. Among authors: yamada y. Clin Genitourin Cancer. 2018 Apr;16(2):142-148. doi: 10.1016/j.clgc.2017.09.008. Epub 2017 Sep 23. Clin Genitourin Cancer. 2018. PMID: 29042308
Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M, Kataoka T, Fujiwara T, Tsukushi S, Takahashi M, Kobayashi E, Yamada Y, Tanaka T, Nezu Y, Hiraga H, Wasa J, Nagano A, Nakano K, Nakayama R, Hamada T, Kawano M, Torigoe T, Sakamoto A, Asanuma K, Morii T, Machida R, Sekino Y, Fukuda H, Oda Y, Ozaki T, Tanaka K. Endo M, et al. Among authors: yamada y. BMC Cancer. 2023 Mar 8;23(1):219. doi: 10.1186/s12885-023-10693-w. BMC Cancer. 2023. PMID: 36890471 Free PMC article.
Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies.
Kaito S, Najima Y, Sadato D, Hirama C, Kishida Y, Nagata A, Konishi T, Yamada Y, Kurosawa S, Yoshifuji K, Shirane S, Shingai N, Toya T, Shimizu H, Haraguchi K, Kobayashi T, Harada H, Okuyama Y, Harada Y, Doki N. Kaito S, et al. Among authors: yamada y. Bone Marrow Transplant. 2024 May 23. doi: 10.1038/s41409-024-02311-5. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38783125
Cross-Education of Muscular Endurance: A Scoping Review.
Song JS, Yamada Y, Kataoka R, Hammert WB, Kang A, Loenneke JP. Song JS, et al. Among authors: yamada y. Sports Med. 2024 May 17. doi: 10.1007/s40279-024-02042-z. Online ahead of print. Sports Med. 2024. PMID: 38758463 Review.
9,728 results